Site notifications

Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

1125 result(s) found, displaying 351 to 375

  • AusPAR: Voretigene neparvovec

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Voretigene neparvovec

  • AusPAR: Defibrotide

    Australian public assessment report (AusPar)
    AusPAR for Defitelio (defibrotide) for treatment of severe hepatic veno-occlusive disease in haematopoietic stem-cell transplantation.

  • AusPAR: Alanylglutamine

    Australian public assessment report (AusPar)
    New AusPAR for Dipeptiven (alanylglutamine) to treat patient in hypercatabolic and/or hypermetabolic states as part of parenteral nutrition.

  • AusPAR: Bevacizumab

    Australian public assessment report (AusPar)
    AusPAR for Mvasi (bevacizumab) for treatment of various cancers

  • AusPAR: Ozanimod hydrochloride

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ozanimod hydrochloride

  • AusPAR: Eculizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Eculizumab

  • AusPAR: Ozempic

    Australian public assessment report (AusPar)
    Ozempic (semaglutide) has been approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

  • AusPAR: Ripretinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ripretinib

  • AusPAR: Pralatrexate

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Pralatrexate

  • AusPAR: Isatuximab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Isatuximab

  • AusPAR: Cemiplimab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Cemiplimab

  • AusPAR: Melatonin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Melatonin

  • AusPAR: Vonicog alfa

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Vonicog alfa

  • AusPAR: Venetoclax

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Venetoclax 

  • AusPAR: Gemtuzumab ozogamicin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Gemtuzumab ozogamicin

  • AusPAR: Venetoclax

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Venetoclax

  • AusPAR: Adalimumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Adalimumab

  • AusPAR: Gilteritinib (as fumarate)

    Australian public assessment report (AusPar)
    New AusPAR for Xospata (gilteritinib as fumarate) for the treatment of relapsed or refractory acute myeloid leukaemia (AML)

  • AusPAR: Ranibizumab (rbe)

    Australian public assessment report (AusPar)
    New AusPAR for Lucentis (ranibizumab) for the treatment of retinopathy of prematurity (ROP)

  • AusPAR: Tafamidis and Tafamidis meglumine

    Australian public assessment report (AusPar)
    New AusPAR for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine) for the treatment of transthyretin amyloid cardiomyopathy